To confirm the immunomodulatory capacity of STAT3 inhibitors, we tested the ability of these two compounds to control the immunosuppressive functions of c-FLIP-expressing monocytes isolated from COVID-19 patients. The gene discussed is CFLAR; the disease is COVID-19.